Gara Jalqabaatti › Hemophilia B
Qorannoo klinikaalii Hemophilia B Ameerikaa Keessatti hirmaatuu
Qorannoo 12 Hemophilia B f bakka adda addaa Ameerikaa Keessatti hirmaatuu jiru.
Magaalota qorannoo baay'ee qaban
- Philadelphia, PAQorannoo 5
- Sacramento, CAQorannoo 4
- Atlanta, GAQorannoo 4
- Houston, TXQorannoo 4
- Los Angeles, CAQorannoo 4
- Ann Arbor, MIQorannoo 4
- Indianapolis, INQorannoo 3
- Seattle, WAQorannoo 3
- San Francisco, CAQorannoo 3
- Nashville, TNQorannoo 3
- Greenville, NCQorannoo 3
- Gainesville, FLQorannoo 3
Naannoon
- CaliforniaQorannoo 7
- FloridaQorannoo 4
- GeorgiaQorannoo 4
- IndianaQorannoo 3
- LouisianaQorannoo 3
- MichiganQorannoo 6
- MissouriQorannoo 3
- New YorkQorannoo 5
- North CarolinaQorannoo 4
- OhioQorannoo 3
- PennsylvaniaQorannoo 6
- TennesseeQorannoo 4
- TexasQorannoo 4
- WashingtonQorannoo 3
Qorannoo yeroo dhihootti haaromfaman
Takkalaa qorannoo (Ingiliffa)
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dhiroota · Haaromfame 02-Onk-2026 · NCT05568719A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 1 hanga 17 · Dhiroota · Haaromfame 23-Ful-2026 · NCT05611801Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
Namoota walitti qabaa jiraSadarkaa 3
138 Months – 206 Months · Dhiroota · Haaromfame 16-Ful-2026 · NCT07080905A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 2 fi ol · Dhiroota · Haaromfame 11-Ful-2026 · NCT06379789Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 27-Hag-2026 · NCT06003387SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 6 fi ol · Saalaa hunda · Haaromfame 21-Hag-2026 · NCT04563520ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 17-Hag-2026 · NCT04398628A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Namoota walitti qabaa jiraSadarkaa 1Hojjettoota fayyaa simatamoo
Umuriin 18 hanga 60 · Saalaa hunda · Haaromfame 02-Ado-2026 · NCT06349473Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 1 hanga 74 · Dhiroota · Haaromfame 01-Ado-2026 · NCT05145127ATHNdataset Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 21-Elb-2026 · NCT06820515An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 19-Gur-2026 · NCT06008938SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 12 hanga 100 · Saalaa hunda · Haaromfame 12-Ama-2026 · NCT04647227Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.